Plasma miR-26a as a diagnostic biomarker regulates cytokine expression in systemic juvenile idiopathic arthritis

Journal of Rheumatology

Volumn 43, Issue 8, 2016, Pages 1607-1614

  Sun, Juan ^a   Feng, Miao ^a   Wu, Fengqi ^a   Ma, Xiaolin ^a   Lu, Jie ^a   Kang, Min ^a   Liu, Zhewei ^a  

^a CAPITAL INSTITUTE OF PEDIATRICS   (China)

Author keywords

Biomarker; Cytokines; MIR 26A; Systemic juvenile idiopathic arthritis

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MICRORNA 26A; TUMOR NECROSIS FACTOR ALPHA; MICRORNA; MIRN26A MICRORNA, HUMAN;

AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CHILD; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IL 6 GENE; INNATE IMMUNITY; JUVENILE RHEUMATOID ARTHRITIS; LUCIFERASE ASSAY; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS; POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; REGULATORY MECHANISM; SCHOOL CHILD; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS; UPREGULATION; ADOLESCENT; BLOOD;

ADOLESCENT; ARTHRITIS, JUVENILE; BIOMARKERS; CHILD; CHILD, PRESCHOOL; CYTOKINES; FEMALE; HUMANS; MALE; MICRORNAS;

EID: 84982803914     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.150593     Document Type: Article

References (36)

1. Nigrovic PA. Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheumatol 2014;66:1405-13.
2. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
3. Steen SO, Iversen LV, Carlsen AL, Burton M, Nielsen CT, Jacobsen S, et al. The circulating cell-free microRNA profile in systemic sclerosis is distinct from both healthy controls and systemic lupus erythematosus. J Rheumatol 2015;42:214-21.
4. Krissansen GW, Yang Y, McQueen FM, Leung E, Peek D, Chan YC, et al. Overexpression of miR-595 and miR-1246 in the sera of patients with active forms of inflammatory bowel disease. Inflamm Bowel Dis 2015;21:520-30.
5. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8.
6. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105:10513-8.
7. Andrews WJ, Brown ED, Dellett M, Hogg RE, Simpson DA. Rapid quantification of microRNAs in plasma using a fast real-time PCR system. Biotechniques 2015;58:244-52.
8. Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol 2014;11:145-56.
9. Duroux-Richard I, Pers YM, Fabre S, Ammari M, Baeten D, Cartron G, et al. Circulating miRNA-125b is a potential biomarker predicting response to rituximab in rheumatoid arthritis. Mediators Inflamm 2014;2014:342524.
10. Ma X, Wu F, Xin L, Su G, He F, Yang Y, et al. Differential plasma microRNAs expression in juvenile idiopathic arthritis. Mod Rheumatol 2016;26:224-32.
11. Cleary AG, Sills JA, Davidson JE. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 2000;27:1568.
12. Tse SM, Laxer RM. New advances in juvenile spondyloarthritis. Nat Rev Rheumatol 2012;8:269-79.
13. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
14. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al; Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease; Council on Cardiovascular Disease in the Young; American Heart Association; American Academy of Pediatrics. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004;110:2747-71.
15. Ozen S, Ruperto N, Dillon MJ, Bagga A, Barron K, Davin JC, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis 2006;65:936-41.
16. Wei C, Kim IK, Kumar S, Jayasinghe S, Hong N, Castoldi G, et al. NF-κB mediated miR-26a regulation in cardiac fibrosis. J Cell Physiol 2013;228:1433-42.
17. Jiang C, Zhu W, Xu J, Wang B, Hou W, Zhang R, et al. MicroRNA-26a negatively regulates toll-like receptor 3 expression of rat macrophages and ameliorates pristane induced arthritis in rats. Arthritis Res Ther 2014;16:R9.
18. Beyan E, Beyan C, Demirezer A, Ertugrul E, Uzuner A. The relationship between serum ferritin levels and disease activity in systemic lupus erythematosus. Scand J Rheumatol 2003;32:225-8.
19. Soyfoo MS, Roth J, Vogl T, Pochet R, Decaux G. Phagocyte-specific S100A8/A9 protein levels during disease exacerbations and infections in systemic lupus erythematosus. J Rheumatol 2009;36:2190-4.
20. Xiu-Yu S, Jia-Yu H, Qiang H, Shu-Hui D. Platelet count and erythrocyte sedimentation rate are good predictors of Kawasaki disease: ROC analysis. J Clin Lab Anal 2010;24:385-8.
21. Yang YH, Yu HH, Chiang BL. The diagnosis and classification of Henoch-Schonlein purpura: an updated review. Autoimmun Rev 2014;13:355-8.
22. Binstadt BA, Levine JC, Nigrovic PA, Gauvreau K, Dedeoglu F, Fuhlbrigge RC, et al. Coronary artery dilation among patients presenting with systemic-onset juvenile idiopathic arthritis. Pediatrics 2005;116:e89-93.
23. Gong GW, McCrindle BW, Ching JC, Yeung RS. Arthritis presenting during the acute phase of Kawasaki disease. J Pediatr 2006;148:800-5.
24. Levy DM, Kamphuis S. Systemic lupus erythematosus in children and adolescents. Pediatr Clin North Am 2012;59:345-64.
25. Gilliam BE, Chauhan AK, Low JM, Moore TL. Measurement of biomarkers in juvenile idiopathic arthritis patients and their significant association with disease severity: a comparative study. Clin Exp Rheumatol 2008;26:492-7.
26. Wittkowski H, Frosch M, Wulffraat N, Goldbach-Mansky R, Kallinich T, Kuemmerle-Deschner J, et al. S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum 2008;58:3924-31.
27. Churov AV, Oleinik EK, Knip M. MicroRNAs in rheumatoid arthritis: altered expression and diagnostic potential. Autoimmun Rev 2015;14:1029-37.
28. Lee DH, Amanat S, Goff C, Weiss LM, Said JW, Doan NB, et al. Overexpression of mir-26a-2 in human liposarcoma is correlated with poor patient survival. Oncogenesis 2013;2:e47.
29. Kim K, Kim JH, Kim I, Lee J, Seong S, Park YW, et al. MicroRNA-26a regulates RANKL-induced osteoclast formation. Mol Cells 2015;38:75-80.
30. Lin YT, Wang CT, Gershwin ME, Chiang BL. The pathogenesis of oligoarticular/polyarticular vs systemic juvenile idiopathic arthritis. Autoimmun Rev 2011;10:482-9.
31. Cazzola M, Ponchio L, de Benedetti F, Ravelli A, Rosti V, Beguin Y, et al. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood 1996;87:4824-30.
32. de Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991;34:1158-63.
33. Martini A. Systemic juvenile idiopathic arthritis. Autoimmun Rev 2012;12:56-9.
34. Chai ZT, Kong J, Zhu XD, Zhang YY, Lu L, Zhou JM, et al. MicroRNA-26a inhibits angiogenesis by down-regulating VEGFA through the PIK3C2α/Akt/HIF-1α pathway in hepatocellular carcinoma. PLoS One 2013;8:e77957.
35. Yang X, Zhang XF, Lu X, Jia HL, Liang L, Dong QZ, et al. MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway. Hepatology 2014;59:1874-85.
36. Icli B, Wara AK, Moslehi J, Sun X, Plovie E, Cahill M, et al. MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling. Circ Res 2013;113:1231-41.